Oncology Site-of-Care Optimization: From Restriction to Strategy

April 23, 2026

This activity will examine how site-of-care policies influence the delivery of oncology therapies and their impact on patient access, outcomes, and total cost of care across hospital, outpatient, and home-based settings. Participants will explore practical strategies for redesigning oncology care pathways to shift appropriate treatments to lower-cost, high-convenience sites of care while preserving safety, quality, and a patient-centered experience. The session will also highlight financial and operational opportunities for health systems to align site-of-care optimization with payer incentives, reimbursement models, and broader value-based care initiatives.

Target Audience

Pharmacists
Pharmacy Technicians
Other Healthcare Professionals

Learning Objectives

At the conclusion of this activity, pharmacists should be able to:

Analyze how site-of-care restrictions for oncology therapies influence patient access, clinical outcomes, and total cost of care across hospital, outpatient, and home-based settings.
Identify strategies to redesign oncology care pathways that shift appropriate treatments to lower-cost, high-convenience sites of care while maintaining safety, quality, and a patient-centered experience.
Evaluate financial and operational opportunities for health systems to align site-of-care optimization with payer incentives, reimbursement models, and value-based care initiatives.

At the conclusion of this activity, pharmacy technicians should be able to:

Analyze how site-of-care restrictions for oncology therapies influence patient access, clinical outcomes, and total cost of care across hospital, outpatient, and home-based settings.
Identify strategies to redesign oncology care pathways that shift appropriate treatments to lower-cost, high-convenience sites of care while maintaining safety, quality, and a patient-centered experience.
Evaluate financial and operational opportunities for health systems to align site-of-care optimization with payer incentives, reimbursement models, and value-based care initiatives.

Course summary

Available credit:

1.00 ACPE Pharmacist
1.00 ACPE Pharmacy Technician
1.00 General CE - Attendance

Course opens:

04/23/2026

Course expires:

06/22/2026

Event starts:

04/23/2026 - 12:00pm CDT

Event ends:

04/23/2026 - 1:00pm CDT

Add to calendar:

FACULTY & PLANNERS

Faculty

Kevin Krueger, PharmD, MBA, MHA

Director of Pharmacy, Infusion Oncology & Research Services

Froedtert and the Medical College of Wisconsin

Steffen Matijevich, PharmD

Oncology Pharmacist

Froedtert Home & Specialty Infusion

Planning Committee

Stacy Lauderdale, PharmD, BCPS

AVP, Evidence-Based Medicine and Drug Information

Vizient, Inc.

Carolyn Liptak, MBA BS Pharm

Pharmacy Executive IV

Vizient, Inc.

Jackie Stokes

Program Services Manager

Vizient, Inc.

Marilu Kelly, MSN, RN, NPD-BC, CHCP

Director, Continuing Education

Vizient, Inc.

Kim Bentley, CHCP

CE Programs Manager

Vizient, Inc.

DISCLOSURE

As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.

Ineligible companies – those companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.

Statement of Content Validity

Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.

FDA Off-Label Use

Faculty presenters are also expected to disclose any discussion of (1) off-label or investigational uses of FDA approved commercial products or devices or (2) products or devices not yet approved in the United States.

Disclaimer

The education provided through this activity is for continuing education purposes only. The views and opinions expressed in this activity are those of the faculty/presenters and do not necessarily reflect the views of Vizient, Inc.

Disclosure Statements

Absence of Relevant Financial Relationships

None of the planners, faculty, or others in a position to control content for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Course Director(s)